ADMA Biologics, Inc. (ADMA)
20.11
+0.39
(+1.98%)
USD |
NASDAQ |
Dec 04, 16:00
20.16
+0.05
(+0.25%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.786B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 0.80% |
| Valuation | |
| PE Ratio | 23.62 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 10.12 |
| Price to Book Value | 11.10 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.1928 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 84.37% |
Profile
| ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ. |
| URL | http://www.admabiologics.com |
| Investor Relations URL | N/A |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 02, 2026 (est.) |
| Last Earnings Release | Nov. 05, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ. |
| URL | http://www.admabiologics.com |
| Investor Relations URL | N/A |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 02, 2026 (est.) |
| Last Earnings Release | Nov. 05, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |